AMUNDI ETF MSCI BRAZIL

  • ISIN: LU1437024992
  • Land: Frankreich

Nachricht vom 17.09.2021 | 09:18

AMUNDI ETF MSCI BRAZIL: Net Asset Value(s)

AMUNDI ETF MSCI BRAZIL (BRZ)
17-Sep-2021 / 09:18 CET/CEST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Net Asset Value(s)

FUND: AMUNDI ETF MSCI BRAZIL

DEALING DATE: 16/09/2021

NAV PER SHARE: USD: 43.7955

NUMBER OF SHARES IN ISSUE: 158247

CODE: BRZ





show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Neufassung der Dividendenpolitik der Allianz SE

02. Dezember 2021, 20:33

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021